^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anti- MESO CAR-T cells

    i
    Other names: anti- MESO CAR-T cells, autologous genetically modified anti- MESO CAR transduced T cells
    Associations

    News

    Trials
    Company:
    Hrain Biotech
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over3years
    The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (clinicaltrials.gov)
    P1, N=10, Recruiting, Shanghai 6th People's Hospital | Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2021 --> Jan 2023
    Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous